Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Net Cash Flow (2017 - 2025)

Historic Net Cash Flow for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to -$146000.0.

  • Aclaris Therapeutics' Net Cash Flow fell 10058.83% to -$146000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.4 million, marking a year-over-year decrease of 36007.43%. This contributed to the annual value of -$15.3 million for FY2024, which is 18353.4% down from last year.
  • Aclaris Therapeutics' Net Cash Flow amounted to -$146000.0 in Q3 2025, which was down 10058.83% from -$5.0 million recorded in Q2 2025.
  • Aclaris Therapeutics' Net Cash Flow's 5-year high stood at $78.2 million during Q2 2021, with a 5-year trough of -$59.8 million in Q3 2021.
  • Its 5-year average for Net Cash Flow is -$1.2 million, with a median of -$555000.0 in 2023.
  • In the last 5 years, Aclaris Therapeutics' Net Cash Flow skyrocketed by 46524.18% in 2021 and then plummeted by 285429.59% in 2024.
  • Aclaris Therapeutics' Net Cash Flow (Quarter) stood at -$26.3 million in 2021, then surged by 37.62% to -$16.4 million in 2022, then surged by 105.12% to $838000.0 in 2023, then crashed by 2854.3% to -$23.1 million in 2024, then skyrocketed by 99.37% to -$146000.0 in 2025.
  • Its Net Cash Flow was -$146000.0 in Q3 2025, compared to -$5.0 million in Q2 2025 and $5.8 million in Q1 2025.